Navigation Links
iCardiac Selected for Multiple Cardiac Safety Studies
Date:6/15/2009

Continues Market Leadership in Highly Automated QT(sm) Evaluation and Helps Sponsors Avoid False Positives

Rochester, NY (PRWEB) June 15, 2009 -- iCardiac Technologies, Inc., a leader in advanced cardiac safety biomarker development and automated QT analysis, announced that it has been chosen by a medium sized pharmaceutical company for cardiac safety evaluation comprising multiple Thorough QT (TQT) Studies.

iCardiac will use its FDA accepted Highly Automated QT method for all contracted studies in addition to using iCardiac's QTbtb(sm) method for avoiding false positives. The sponsor selected iCardiac because of both iCardiac's cardiac safety expertise in relation to complex drug development programs as well as the extensive validation of iCardiac's COMPAS technology. COMPAS Highly Automated QT leads the industry in validation and deployments covering over 1.5 million ECGs analyzed with partners including pharmaceutical companies, academia, regulators, as well as having been cross validated with result from five leading ECG core labs.

"We are enthusiastic about the markets continued acceptance of iCardiac's Highly Automated QT solution," said Sasha Latypova, Executive Vice President. "In addition to increasing the robustness of cardiac safety evaluation and reducing the likelihood of false positives through the use of iCardiac's proprietary QTbtb method, the sponsor will realize increased economic efficiencies in comparison to traditional QT studies."

About iCardiac Technologies:
iCardiac Technologies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies. iCardiac's analysis service provides drug developers with more precise and cost-effective methods for
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. iCardiac Reports Significant Revenue Growth and Profitability
2. iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company
3. Biomaxx Systems Inc. Selected as Technical Consultant By Southern Cross Agricultural Developments
4. Solazyme, Inc. Selected by AlwaysOn as a GoingGreen 100 Top Private Company Award Winner
5. Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project
6. AG Mednet Selected By Massachusetts General Hospital to Transport 3D Post-Processing Images
7. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
8. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
9. Solazyme Selected for National Institute of Standards and Technology Award
10. Advanced Life Sciences to Present Data from Selected Cethromycin Clinical Trials at the 45th Annual Meeting of the Infectious Diseases Society of America
11. Genstructs Andrea Matthews Selected for Mass High Techs People to Watch Under 30
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/lkcspr/2015_strategies ... "2015 Strategies in European Immunoprotein Diagnostic ... This new 273-page report provides ... including emerging tests, technologies, instrumentation, sales forecasts, ... suppliers. Companies Mentioned: - ...
(Date:6/1/2015)... June 1, 2015  OncoSec Medical Inc. ("OncoSec") ... intratumoral cancer immunotherapies, today announced a collaboration with ... Veterinary Medicine to test ImmunoPulse™ IL-12 as an ... primary goals of the canine study are to ... of ImmunoPulse™ IL-12 and validate key clinical biomarkers. ...
(Date:6/1/2015)... Hutchison China MediTech Limited ... (publ) ("AstraZeneca"), Hutchison MediPharma Limited,s ("HMP") collaboration partner, ... clinical trial of HMP,s c-Met inhibitor savolitinib (AZD6094) ... cell lung cancer ("NSCLC"). AZD9291 is ... receptor (EGFR). Preliminary data on the activity of ...
(Date:5/31/2015)... 31, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... oncology and drug-delivery therapies, today announced interim findings ... its investigational new drug PEGPH20 for the potential ... The encouraging interim data was presented today ... meeting in an oral presentation by Principal Investigator ...
Breaking Biology Technology:OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 2OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 3OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 4Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 2Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 3Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 2Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 3Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 4Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 5
... Aug. 2, 2011 Cephalon, Inc. (Nasdaq: CEPH ... million, a 2 percent increase compared to net sales of ... per common share for the period was $1.54 compared to ... and certain other items, adjusted net income for the second ...
... 2011 Enzymatics, Inc., ( www.enzymatics.com ) a leading ... Boston Chamber of Commerce with a "Top 10 Small ... Honorees include dynamic small and high growth businesses in ... excellence, product innovation, and social responsibility.  An awards luncheon ...
... N.Y. Every year, millions of people contend with ... their pain, Cornell University engineers in Ithaca and doctors ... City have created a biologically based spinal implant that ... Lawrence Bonassar, Ph.D., associate professor of biomedical engineering ...
Cached Biology Technology:Cephalon Reported Financial Results for the Second Quarter of 2011 2Cephalon Reported Financial Results for the Second Quarter of 2011 3Cephalon Reported Financial Results for the Second Quarter of 2011 4Cephalon Reported Financial Results for the Second Quarter of 2011 5Cephalon Reported Financial Results for the Second Quarter of 2011 6Cephalon Reported Financial Results for the Second Quarter of 2011 7Cephalon Reported Financial Results for the Second Quarter of 2011 8Cephalon Reported Financial Results for the Second Quarter of 2011 9Cephalon Reported Financial Results for the Second Quarter of 2011 10Cephalon Reported Financial Results for the Second Quarter of 2011 11Cephalon Reported Financial Results for the Second Quarter of 2011 12Enzymatics Honored With a Top 10 Small Business of the Year Award 2In the battle to relieve back aches, Cornell researchers create bioengineered spinal disc implants 2In the battle to relieve back aches, Cornell researchers create bioengineered spinal disc implants 3
(Date:5/29/2015)... Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ) ... Recognition Market by Solution, by Software, by Hardware, ... report to their offering. The ... become more efficient and cost effective. This has ... from the commercial sector. The development of 3D ...
(Date:5/22/2015)... 22, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... be ending its promotional pricing and making the Wocket generally ... Laurence Savin , Head of Marketing said, "We,ve extended the ... the end of May. To get your wocket at this ... open the store on June 1, you,ll receive a unique ...
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. (NASDAQ: ... its wholly owned subsidiary, 3D-ID LLC, a company engaged ... Battelle for the biometrics technology portion of the recently ... from the Department of the Army. 3D-ID ... developed for government, law enforcement and security agencies. ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... recently discovered that a chemical chain reaction that controls ... could mean the difference between normal growth and cancer. ... Cell, describes how organs can grow uncontrollably huge and ... This chain reaction, a domino-like chain of events ...
... HONOLULU, Sept. 20 Women with low levels of vitamin ... a study led by the University of Pittsburgh Graduate School ... meeting of the American Society for Bone and Mineral Research ... professor of epidemiology, and colleagues evaluated patient data on 400 ...
... Nile virus first struck New York City in 1999, ... public health officials alike, showing that even affluent, urban ... virus has been widely studied, there is still little ... between urban and rural areas. Assistant professor at ...
Cached Biology News:Controlling for size may also prevent cancer 2Low vitamin D linked to higher risk of hip fracture 2UGA Odum School of Ecology professor receives grant to study West Nile Virus in NYC 2
Nestin, Human...
Ezrin/Radixin/Moesin Antibody...
... Taura Syndrome Virus Coat Protein ... tested applications). ... MNDIPITNQN VVLSKNVTDN LFEVQDQALI ESLSRDVLLH NDSWTSSDDE ... terminal amino acids 25/100 of ...
JAB1 Immunogen: Synthetic peptide, conjugated to KLH, corresponding to residues S(201) E Y Q T I P L N K I E D F G V(216) of human JAB1. The sequence is identical in mouse and rat. Storage: -...
Biology Products: